Akrit Sodhi

Akrit Sodhi

Auto-generated profile, based on publicly available information

Akrit Sodhi

Wilmer Eye Institute, Johns Hopkins School of Medicine, Baltimore, USA

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 August 2013 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
XXXiaoban Xin
Xiaoban Xin
MRMurilo Rodrigues
Murilo Rodrigues
MUMahaa Umapathi
Mahaa Umapathi
FKFabiana Kashiwabuchi
Fabiana Kashiwabuchi
TMTao Ma
Tao Ma
ASAkrit Sodhi
Akrit Sodhi
Significance: Ischemic retinopathies include a diverse group of diseases in which immature retinal vasculature or damage to mature retinal vessels leads to retinal ischemia. The anticipated rise in the worldwide prevalence of diabetes will result in a concurrent increase in the number of patients with vision impairment from diabetic eye disease, the most common cause of ischemic retinopathy. We set out to identify novel hypoxia-inducible genes that promote vascular permeability and may therefore play a role in the pathogenesis of diabetic eye disease. We demonstrate that angiopoietin-like 4 (ANGPTL4) is up-regulated by the transcriptional enhancer, hypoxia-inducible factor-1 in hypoxic retinal Müller cells, and can promote vascular permeability. Our findings suggest that ANGPTL4 may be a potential therapeutic target for ischemic retinopathies.

9 January 2016 in Oncotarget
Verified
Journal Article
Open access
PDF file
KHKe Hu
Ke Hu
SBSavalan Babapoor-Farrokhran
Savalan Babapoor-Farrokhran
MRMurilo Rodrigues
Murilo Rodrigues
MDMonika Deshpande
Monika Deshpande
BPBrooks Puchner
Brooks Puchner
ASAkrit Sodhi
Akrit Sodhi
Hypoxia-inducible factor 1 upregulation of both VEGF and ANGPTL4 is required to promote the angiogenic phenotype in uveal melanoma

26 May 2015 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
SBSavalan Babapoor-Farrokhran
Savalan Babapoor-Farrokhran
KJKathleen Jee
Kathleen Jee
BPBrooks Puchner
Brooks Puchner
SHSyed Junaid Hassan
Syed Junaid Hassan
XXXiaoban Xin
Xiaoban Xin
ASAkrit Sodhi
Akrit Sodhi
Significance: In proliferative diabetic retinopathy (PDR), the most vision-threatening sequela of diabetic eye disease, retinal ischemia leads to increased expression of angiogenic factors that promote neovascularization. Although therapies targeting the potent angiogenic mediator vascular endothelial growth factor have been remarkably successful for the treatment of diabetic macular edema, this approach has not proven sufficient to prevent the development of retinal neovascularization, implicating additional angiogenic factor(s) in PDR pathogenesis. We demonstrate here that angiopoietin-like 4 is a potent angiogenic mediator with markedly increased expression in the eyes of PDR patients. Our studies identify a novel therapeutic target for the treatment of ocular neovascular disease and may have broad implications for the treatment of other diseases dependent on pathologic angiogenesis.

5 August 2020 in Science Translational Medicine
Verified
Journal Article
Closed access
ZLZhiping Liu
Zhiping Liu
JXJiean Xu
Jiean Xu
QMQian Ma
Qian Ma
XZXiaoyu Zhang
Xiaoyu Zhang
QYQiuhua Yang
Qiuhua Yang
YHYuqing Huo
Yuqing Huo
Increased glycolysis facilitates reciprocal activation between myeloid cells and endothelial cells in pathological retinal angiogenesis.

18 October 2013 in Diabetes
Verified
Journal Article
Open access
PDF file
MRMurilo Rodrigues
Murilo Rodrigues
XXXiaoban Xin
Xiaoban Xin
KJKathleen Jee
Kathleen Jee
SBSavalan Babapoor-Farrokhran
Savalan Babapoor-Farrokhran
FKFabiana Kashiwabuchi
Fabiana Kashiwabuchi
ASAkrit Sodhi
Akrit Sodhi
In proliferative diabetic retinopathy (PDR), retinal ischemia promotes neovascularization (NV), which can lead to profound vision loss in diabetic patients. Treatment for PDR, panretinal photocoagulation, is inherently destructive and has significant visual consequences. Therapies targeting vascular endothelial growth factor (VEGF) have transformed the treatment of diabetic eye disease but have proven inadequate for treating NV, prompting exploration for additional therapeutic options for PDR patients. In this regard, extracellular proteolysis is an early and sustained activity strictly required for NV. Extracellular proteolysis in NV is facilitated by the dysregulated activity of matrix metalloproteinases (MMPs). Here, we set out to better understand the regulation of MMPs by ischemia in PDR. We demonstrate that accumulation of hypoxia-inducible factor-1α in Müller cells induces the expression of VEGF, which, in turn, promotes increased MMP-2 expression and activity in neighboring endothelial cells (ECs). MMP-2 expression was detected in ECs in retinal NV tissue from PDR patients, whereas MMP-2 protein levels were elevated in the aqueous of PDR patients compared with controls. Our findings demonstrate a complex interplay among hypoxic Müller cells, secreted angiogenic factors, and neighboring ECs in the regulation of MMP-2 in retinal NV and identify MMP-2 as a target for the treatment of PDR.

22 June 2023 in JCI Insight
Verified
Journal Article
Open access
PDF file
HLHaitao Liu
Haitao Liu
SGSayan Ghosh
Sayan Ghosh
TVTanuja Arun Vaidya
Tanuja Arun Vaidya
SBSridhar Bammidi
Sridhar Bammidi
CHChao Huang
Chao Huang
DSDebasish Sinha
Debasish Sinha
Diabetic retinopathy (DR) is a leading cause of blindness in working-age adults and remains an important public health issue worldwide. Here we demonstrate that the expression of stimulator of interferon genes (STING) is increased in patients with DR and animal models of diabetic eye disease. STING has been previously shown to regulate cell senescence and inflammation, key contributors to the development and progression of DR. To investigate the mechanism whereby STING contributes to the pathogenesis of DR, diabetes was induced in STING -KO mice and STING GT (loss-of-function mutation) mice, and molecular alterations and pathological changes in the retina were characterized. We report that retinal endothelial cell senescence, inflammation, and capillary degeneration were all inhibited in STING -KO diabetic mice; these observations were independently corroborated in STING GT mice. These protective effects resulted from the reduction in TBK1, IRF3, and NF-κB phosphorylation in the absence of STING. Collectively, our results suggest that targeting STING may be an effective therapy for the early prevention and treatment of DR.